Background: Plasma-based biomarkers would be potential biomarkers for early diagnosis of
Alzheimer's disease (AD) because they are more available and cost-effective than …

Introduction There is increasing evidence that phosphorylated tau (P‐tau181) is a specific
biomarker for Alzheimer's disease (AD) pathology, but its potential utility in non‐White …

To assess plasma phosphorylated tau181 (p-tau181) as a progression biomarker in
Alzheimer's disease (AD), we examined longitudinal plasma p-tau181 of 1184 participants …

Background There is an urgent need for cost-effective, easy-to-measure biomarkers to
identify subjects who will develop Alzheimer's disease (AD), especially at the pre …

Objective To determine if plasma tau phosphorylated at threonine 181 (p‐tau181)
distinguishes pathology‐confirmed Alzheimer's disease (AD) from normal cognition (NC) …

INTRODUCTION Detection of Alzheimer's disease (AD) pathophysiology among individuals
with mild cognitive changes and those experiencing subjective cognitive decline (SCD) …

Abstract Plasma phosphorylated-tau181 (p-tau181) showed the potential for Alzheimer's
diagnosis and prognosis, but its role in detecting cerebral pathologies is unclear. We aimed …

Background Recent studies suggest that plasma phosphorylated tau181 (p-tau181) is a
highly specific biomarker for Alzheimer's disease (AD)-related tau pathology. It has great …

Objectives Plasma P-tau181 is an increasingly established diagnostic marker for
Alzheimer's disease (AD). Further validation in prospective cohorts is still needed, as well as …

Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for
amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer's disease …